Shukra Pharma.

Who are the top shareholders of the Shukra Pharma.?

The top shareholders of Shukra Pharma are Anar Project Private Limited with 18.78% and Yogesh Biharilal Parikh with 19.18%. Individual investors hold 9.29%, with no pledged promoter holdings or mutual funds/foreign institutional investors involved.

The top shareholders of Shukra Pharma include Anar Project Private Limited, which holds the highest promoter stake at 18.78%. Additionally, the highest public shareholder is Yogesh Biharilal Parikh, who owns 19.18%. Individual investors collectively hold 9.29% of the company’s shares. Notably, there are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors holding shares.

how big is Shukra Pharma.?

As of October 2023, Shukra Pharmaceuticals Ltd has a market capitalization of 592.00 Cr, classifying it as a Micro Cap company, with recent net sales of 32.59 Cr and net profit of 9.58 Cr over the last four quarters.

Market Cap: Shukra Pharmaceuticals Ltd has a market capitalization of 592.00 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes Mar'25, Dec'24, Sep'24, and Jun'24, is 32.59 Cr. The sum of Net Profit for the same period is 9.58 Cr. This data is based on Standalone financials.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the latest annual period ending in Mar'24. The Shareholder's Funds are reported at 57.64 Cr, and the Total Assets amount to 77.84 Cr.

What does Shukra Pharma. do?

Shukra Pharmaceuticals Ltd manufactures and trades pharmaceutical formulations and conducts laboratory testing. As of March 2025, it reported net sales of 13 Cr and a net profit of 5 Cr, with a market cap of Rs 604 Cr.

Overview:<BR>Shukra Pharmaceuticals Ltd is engaged in the manufacturing and trading of pharmaceutical formulations and laboratory testing within the Pharmaceuticals & Biotechnology industry, classified as a Micro Cap company.<BR><BR>History:<BR>Shukra Pharmaceuticals Ltd was established in March 1993, originally under the name Relish Pharmaceuticals Limited, which was changed to its current name effective September 22, 2016. The most recent quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 13 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 5 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 604 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 62.00<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.74%<BR>- Debt Equity: -0.28<BR>- Return on Equity: 17.65%<BR>- Price to Book: 10.90<BR><BR>Contact Details:<BR>- Address: 3 rd Floor Dev House, Opp WIAA Office Judges Bungalo Ahmedabad Gujarat : 380054<BR>- Tel: 91-079-66522247/27498515<BR>- Email: info@relishpharma.com<BR>- Website: http://www.shukrapharmeceuticals.com

What is the bonus history of the Shukra Pharma.?

Shukra Pharma recently announced a 3:1 bonus issue, with an ex-date of April 19, 2024, and a record date of April 20, 2024. Shareholders will receive three additional shares for every one share held.

Shukra Pharma has a recent bonus issue history where they announced a 3:1 bonus. The ex-date for this bonus issue is set for April 19, 2024, and the record date is April 20, 2024. This means that for every one share held, shareholders will receive three additional shares. If you have any more questions about the company or its activities, feel free to ask!

Has Shukra Pharma. declared dividend?

Yes, Shukra Pharmaceuticals Ltd has declared a 10% dividend, amounting to 1 per share, with an ex-date of September 23, 2024. Despite recent periods showing no dividend returns, the company has demonstrated exceptional price performance over the years.

Shukra Pharmaceuticals Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 23 Sep 24<BR><BR>Dividend Yield: 0.74%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 123.5%, with no dividend return, resulting in a total return of 123.5%.<BR><BR>Over the past year, the price return was 48.12%, with no dividend return, leading to a total return of 48.12%.<BR><BR>In the last 2 years, the price return was 280.55%, with no dividend return, resulting in a total return of 280.55%.<BR><BR>Over the last 3 years, the price return was 3587.56%, with a dividend return of 9.64%, culminating in a total return of 3597.2%.<BR><BR>In the past 4 years, the price return was 3975.57%, with a dividend return of 16.88%, leading to a total return of 3992.45%.<BR><BR>Over the last 5 years, the price return was 8670.9%, with a dividend return of 31.45%, resulting in a total return of 8702.35%.<BR><BR>Overall, Shukra Pharmaceuticals Ltd has declared a dividend, and despite the recent periods showing no dividend returns, the total returns over the years have been exceptionally high, indicating strong price performance.

Who are the peers of the Shukra Pharma.?

Shukra Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Medicamen Biotec, Jenburkt Pharma, Kerala Ayurveda, and Ind-Swift Labs. Among these, Sun Pharma, Cipla, and Dr Reddy's Labs show excellent management and growth, while Shukra Pharma has good growth and capital structure.

Peers: The peers of Shukra Pharma. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Medicamen Biotec, Jenburkt Pharma, Kerala Ayurveda, Ind-Swift Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at Shukra Pharma., Medicamen Biotec, Jenburkt Pharma, and Accent Microcell. Below Average management risk is noted at Kerala Ayurveda and Ind-Swift Labs. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Good growth is seen at Shukra Pharma. Below Average growth is present at Divi's Lab., Torrent Pharma, Medicamen Biotec, Jenburkt Pharma, Kerala Ayurveda, and Ind-Swift Labs. Excellent capital structure is noted at Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, and Medicamen Biotec, while Good capital structure is found at Shukra Pharma. and Torrent Pharma. Below Average capital structure is observed at Kerala Ayurveda and Ind-Swift Labs.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.96%, while the lowest is Medicamen Biotec at -16.64%. Shukra Pharma.'s own 1-year return is 34.14%, which is significantly higher than Medicamen Biotec but lower than Divi's Lab. Additionally, the peers with negative six-month returns include Medicamen Biotec, Jenburkt Pharma, and Ind-Swift Labs.

Is Shukra Pharma. overvalued or undervalued?

As of May 7, 2024, Shukra Pharma is considered very expensive and overvalued with a PE Ratio of 63.03, significantly higher than its peers, despite a 54.08% return over the past year, indicating a lack of growth expectations.

As of 7 May 2024, the valuation grade for Shukra Pharma. has moved from expensive to very expensive, indicating a significant shift in its perceived value. The company is currently considered overvalued. Key ratios include a PE Ratio of 63.03, an EV to EBITDA of 46.20, and a Price to Book Value of 11.12, all of which are substantially higher than industry averages.<BR><BR>In comparison to its peers, Shukra Pharma.'s PE Ratio is notably higher than Sun Pharma. (35.25) and Cipla (22.99), which are categorized as expensive and attractive, respectively. Additionally, while Divi's Lab is also classified as very expensive with a PE of 79.33, Shukra Pharma. still stands out with a significantly lower PEG Ratio of 0.00, suggesting a lack of growth expectations. Notably, Shukra Pharma. has outperformed the Sensex over the past year with a return of 54.08% compared to the Sensex's 7.65%, further complicating its valuation narrative.

Who are in the management team of Shukra Pharma.?

As of March 2022, the management team of Shukra Pharma includes Dakshesh Shah (Chairman & Managing Director), Payal Mehta, Sanskruti Patel, and Dhruvin Shah (all Executive Directors), along with independent directors Bhoomiben Patel, Sarjeevan Singh, Sonal Deepalbhai Gandhi, and Pinki Nirmal Sagar.

As of March 2022, the management team of Shukra Pharma includes:<BR><BR>1. Dakshesh Shah - Chairman & Managing Director<BR>2. Payal Mehta - Executive Director<BR>3. Sanskruti Patel - Executive Director<BR>4. Dhruvin Shah - Executive Director<BR>5. Bhoomiben Patel - Independent Director<BR>6. Sarjeevan Singh - Independent Director<BR>7. Sonal Deepalbhai Gandhi - Independent Director<BR>8. Pinki Nirmal Sagar - Independent Director<BR><BR>The team comprises a mix of executive and independent directors, with Dakshesh Shah serving as the Chairman and Managing Director.

How has been the historical performance of Shukra Pharma.?

Shukra Pharma's historical performance shows significant fluctuations, with net sales rising from INR 5.69 crore in March 2019 to INR 32.59 crore in March 2025, despite a decline from INR 74.57 crore in March 2024. While total assets and cash flow improved, recent decreases in sales and profits suggest potential challenges ahead.

Answer:<BR>The historical performance of Shukra Pharma shows significant fluctuations in its financial metrics over the years, particularly from March 2019 to March 2025.<BR><BR>Breakdown:<BR>Shukra Pharma's net sales have seen a dramatic increase from INR 5.69 crore in March 2019 to INR 32.59 crore in March 2025, although there was a notable decline in sales from INR 74.57 crore in March 2024. Total operating income followed a similar trend, peaking at INR 74.57 crore in March 2024 before dropping to INR 32.59 crore in March 2025. The company's total expenditure, excluding depreciation, also fluctuated, reaching INR 55.17 crore in March 2024 and decreasing to INR 19.86 crore in March 2025. Operating profit (PBDIT) showed a peak of INR 22.22 crore in March 2024, followed by a decline to INR 16.94 crore in March 2025. Profit before tax reached its highest at INR 19.88 crore in March 2024, then fell to INR 13.34 crore in March 2025, while profit after tax also decreased from INR 18.54 crore in March 2024 to INR 9.58 crore in March 2025. The company's total assets increased from INR 33.55 crore in March 2020 to INR 86.77 crore in March 2025, reflecting growth in both current and non-current assets. Total liabilities also rose, from INR 33.55 crore in March 2020 to INR 86.77 crore in March 2025, indicating an increase in financial obligations. Cash flow from operating activities improved significantly, showing a positive cash flow of INR 7 crore in March 2025 compared to a negative cash flow of INR 5 crore in March 2024. Overall, while Shukra Pharma has experienced growth in certain areas, the recent decline in sales and profits indicates potential challenges ahead.

Is Shukra Pharma. technically bullish or bearish?

As of December 4, 2025, the technical trend has shifted to bullish, supported by strong indicators like bullish MACD and Bollinger Bands, despite a mildly bearish KST signal on the monthly chart.

As of 4 December 2025, the technical trend has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The weekly and monthly MACD are both bullish, and Bollinger Bands also indicate a bullish trend on both time frames. Daily moving averages confirm a bullish outlook. Although the KST shows a mildly bearish signal on the monthly, the overall strength of the bullish indicators outweighs this. The stock has demonstrated significant outperformance compared to the Sensex over multiple time frames, further reinforcing the bullish sentiment.

When is the next results date for Shukra Pharmaceuticals Ltd?

The next results date for Shukra Pharmaceuticals Ltd is 04 February 2026.

The next results date for Shukra Pharmaceuticals Ltd is scheduled for 04 February 2026.

Are Shukra Pharmaceuticals Ltd latest results good or bad?

Shukra Pharmaceuticals Ltd's latest Q3 FY26 results are strong, with a net profit increase of 755.46% and revenue growth of 565.48%. However, concerns about sustainability and a high price-to-earnings ratio suggest a cautious outlook for investors.

Shukra Pharmaceuticals Ltd's latest results for Q3 FY26 are quite impressive, showcasing a significant turnaround in performance. The company reported a net profit of ₹20.36 crore, which marks a staggering increase of 755.46% quarter-over-quarter. Additionally, revenue surged to ₹39.13 crore, reflecting a growth of 565.48% from the previous quarter.<BR><BR>The operating margin reached an all-time high of 69.33%, and the profit after tax (PAT) margin stood at 52.03%, both of which are considered best-in-class metrics within the pharmaceutical sector. This performance indicates a strong operational improvement and effective cost management.<BR><BR>However, while the results are strong, there are concerns regarding the sustainability of such dramatic improvements, especially given the company's history of inconsistent performance. The stock is currently trading at a high price-to-earnings ratio of 142 times, significantly above the industry average, which raises questions about its valuation.<BR><BR>In summary, the latest results can be considered good in terms of financial performance, but the high valuation and past inconsistencies suggest a cautious outlook moving forward. Investors should monitor how the company maintains this momentum in the coming quarters.

Should I buy, sell or hold Shukra Pharmaceuticals Ltd?

Why is Shukra Pharmaceuticals Ltd falling/rising?

As of 16-Mar, Shukra Pharmaceuticals Ltd's stock price is currently at 40.65, reflecting a 2.42% increase after a trend reversal. Despite this rise, the stock has a year-to-date decline of 31.39% and a significant drop in investor participation, indicating mixed short-term trends.

As of 16-Mar, Shukra Pharmaceuticals Ltd's stock price is rising, currently at 40.65, reflecting a change of 0.96 or 2.42% increase. This upward movement follows a trend reversal after three consecutive days of decline. Additionally, the stock has outperformed its sector by 3.54% today, indicating a stronger performance relative to its peers.<BR><BR>Despite the recent rise, it is important to note that the stock has experienced significant declines over the longer term, with a year-to-date drop of 31.39%. However, over the past year, it has shown a remarkable increase of 65.38%, and an extraordinary rise of 3681.40% over the last three years. <BR><BR>The stock's current price is higher than its 20-day and 200-day moving averages, although it is lower than its 5-day, 50-day, and 100-day moving averages. This suggests a mixed trend in the short term. Furthermore, there has been a notable decrease in investor participation, with delivery volume falling by 76.69% compared to the 5-day average, which could indicate a lack of confidence among investors despite the current price increase. <BR><BR>Overall, the stock's rise today can be attributed to a trend reversal and relative outperformance in the sector, even as it faces challenges with declining investor participation and significant losses in the year-to-date performance.

Which are the latest news on Shukra Pharma.?